Journal Article

Efficacy of early ofatumumab versus late-teriflunomide switch: subgroup analysis by prior DMT exposure and age

Francesco, Sacca, Ralf, Gold, Jerome, de Seze, Derrick, Robertson, Ronald, Zielman, Amin, Azmon, Jeffrey, Cohen, Sibyl, Wray, Heinz, Wiendl, Ludwig, Kappos

2023

Overview

Clinical and MRI outcomes from ASCLEPIOS and ALITHIOS were analysed in patients receiving Ofatumumab (OMB) during the core and extension (OMB-OMB) and patients who switched from Teriflunomide (TER) to OMB in the extension (TER-OMB). Of the 1882 patients randomized, 946/936 received OMB/TER and 690/677 continued/were switched to OMB in the extension.Switching from TER to OMB in the extension significantly reduced the ARR by 68.3–76.6%; continuing OMB in the extension further reduced ARR by 39.9–65.1%. Within the prior DMT subgroups, the lowest mean ARR was achieved in patients in the OMB-OMB group with ≤1 DMT (0.046–0.049). Switching to/continuing OMB was associated with a consistent numerical reduction in the risk of 3/6mCDW with the greatest benefit observed in patients on continuous OMB with ≤1 DMT or ≤40 years old. The almost complete suppression of T1 Gd+ activity seen in those randomised to OMB in the core was mirrored in the TER-OMB groups in the extension (90.00–100% across all prior DMT and age subgroups) and sustained in the OMB-OMB group. New/enlarging T2 lesions showed a similar, though delayed, suppression in the TER-OMB group.Switching from TER to OMB in ALITHIOS reduced clinical and MRI disease activity across all prior DMT and age subgroups.

• Publisher: BMJ Publishing Group Ltd,BMJ Publishing Group LTD
• Subject: Association of British Neurologists: Annual Meeting Abstracts 2023 / Monoclonal antibodies